Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Michael J. Fox Foundation, Van Andel Research Institute And The Cure Parkinson's Trust Collaborate To Assess The Clinical Use And Development Of Nilotinib In Parkinson's Disease


News provided by

The Michael J. Fox Foundation

12 Jul, 2016, 15:08 GMT

Share this article

Share toX

Share this article

Share toX

-- Investigators will focus on safety for long-term use in non-cancer patients

-- Partners aim to design and co-fund a multi-site trial to begin in 2017; trial endpoints would include precise biological measures of drug activity as well as symptomatic response

-- Patients and clinicians urged to proceed with caution

NEW YORK and GRAND RAPIDS, Michigan and LONDON, July 12, 2016 /PRNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF), Van Andel Research Institute (VARI) and The Cure Parkinson's Trust (CPT) today announced plans to collaborate on the clinical development of nilotinib, a chronic myelogenous leukemia drug that has shown potential in preliminary studies as a treatment for Parkinson's disease. As part of these efforts, the organizations aim to design and co-fund a therapeutic development program including a double-blind, placebo-controlled clinical trial of nilotinib expected to begin in 2017.

"We are enthusiastic about further investigating early clinical results that indicated some level of nilotinib safety and tolerability in Parkinson's patients," said Todd Sherer, PhD, chief executive officer of MJFF, one of three authors of an editorial published today in the Journal of Parkinson's Disease (JPD). Co-authored by Sherer, Patrik Brundin, MD, PhD, director of VARI's Center for Neurodegenerative science and co-editor-in-chief of JPD, and Richard Wyse, MD, director of research and development at CPT, the editorial summarizes the current status of nilotinib for Parkinson's, acknowledging the promise of intriguing clinical and pre-clinical findings but urging caution on the part of patients and clinicians until more research is done.

Collaboration Aims to Verify and Expand on Previous Nilotinib Findings
The goal of the MJFF/VARI/CPT collaboration is to advance nilotinib as a potentially disease-modifying and/or symptomatic Parkinson's treatment by first and foremost expanding on early safety findings and potential side effects in order to better understand the implications of long-term use of nilotinib in non-cancer patients.

The program also will rigorously address early-stage preclinical and clinical findings about the drug. Earlier studies have demonstrated some preliminary data on measures of drug penetration into the brain (as measured in spinal fluid) and exploratory biochemical measures. The MJFF/VARI/CPT study aims to verify and expand on these findings.

Preclinical studies have shown that nilotinib may protect neuronal cells from Parkinson's pathology by inhibiting the activity of a protein known as c-Abl, but additional work is required to understand the relationship between nilotinib dosing and c-Abl activity. The role of c-Abl as a cancer driver in myelogous leukemia is well known and, as recent work by others in the field has demonstrated, it may also play a role in Parkinson's disease. The study also aims to explore and independently verify nilotinib's potential to treat Parkinson's symptoms.

Patients are encouraged to create a profile on Fox Trial Finder (www.foxtrialfinder.org) to be notified if they are a likely match for the planned nilotinib trial or other trials in need of research volunteers.

Patients and Clinicians Urged to Proceed with Caution
There is reason for optimism about the promise of nilotinib in Parkinson's disease, both as a therapy that might reduce symptoms in the short term and potentially even as a disease-modifying treatment (one capable of slowing or stopping Parkinson's progression, something no current treatment can do). Nonetheless, patients and clinicians are urged to wait for further safety data before considering adding the drug to their treatment regimens at this time. There is not yet enough information to assert that it works in Parkinson's and, perhaps most critically, that it is safe to take long-term.

"We are enthusiastic about this partnership, which demonstrates the commitment of those involved to leave no stone unturned in the quest to find better treatments for Parkinson's," said Tom Isaacs, co-founder of The Cure Parkinson's Trust. "It is imperative that we work urgently with the Parkinson's community — my fellow patients as well as drug developers — as we continue vetting nilotinib's potential to address the medical needs of people with Parkinson's in a safe and effective manner."

MJFF, CPT and VARI have long recognized the potential of repositioned drugs — that is, drugs approved to treat other diseases, which have also shown promise in Parkinson's — to significantly cut down on the time and cost of moving new Parkinson's treatments from the lab to clinical care. An investigation of the high-blood-pressure drug isradipine funded by MJFF from 2007–2015 has recently entered Phase III clinical testing. CPT and VARI have partnered since 2014 on their Linked Clinical Trials (LCT) initiative, which is dedicated to funding the development of repositioned medications with potential to slow or reverse Parkinson's disease. Through LCT, The Cure Parkinson's Trust and Van Andel Research Institute have committed to work with The Michael J. Fox Foundation to further explore the possibility of nilotinib as a Parkinson's treatment, and to educate Parkinson's patients and families about the drug.

About The Michael J. Fox Foundation for Parkinson's Research
As the world's largest nonprofit funder of Parkinson's research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, industry leaders, government research funders and regulators, clinical trial participants, donors and volunteers. In addition to funding more than $600 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. The Foundation increases the flow of participants into Parkinson's disease clinical trials with its online tools Fox Trial Finder and Fox Insight; sponsors a landmark, international study to find reliable and consistent biomarkers of Parkinson's progression; promotes Parkinson's awareness through high-profile events and outreach; advocates for state and federal policies that support medical research and increased access to health care; and coordinates the involvement of thousands of Team Fox members and grassroots volunteers around the world.

For more information, visit us on the Web, Facebook, Twitter, LinkedIn, Instagram and Pinterest.

About Van Andel Research Institute
Van Andel Institute (VAI) is an independent biomedical research and science education organization committed to improving the health and enhancing the lives of current and future generations. Established by Jay and Betty Van Andel in 1996 in Grand Rapids, Michigan, VAI has grown into a premier research and educational institution that supports the work of more than 360 scientists, educators and staff. Van Andel Research Institute (VARI), the research division of VAI, is dedicated to determining the epigenetic, genetic, molecular and cellular origins of cancer, Parkinson's and other diseases and translating those findings into effective therapies. The Institute's scientists work in on-site laboratories and participate in collaborative partnerships that span the globe.

About The Cure Parkinson's Trust
The Cure Parkinson's Trust was set up in 2005 by four people living with the condition. It has one bold aim – to cure Parkinson's. People living with Parkinson's shape the charity's policies and approach. Its innovative Linked Clinical Trials Programme focuses on drug repurposing, prioritizing potentially disease modifying treatments and moving them forward to clinical trial. Nilotinib has been explored through this programme since 2012. This programme has been developed in collaboration with the Van Andel Institute and to date six trials are underway on drugs used in other conditions, and two regenerative medicine trial, of which show the potential to slow, stop or reverse Parkinson's. www.cureparkinsons.org.uk

Related Links

https://www.michaeljfox.org

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.